EGFR, KRAS and EML4‐ALK are well‐understood oncogenic drivers of lung cancer 22, 23, 24, and patients with lung tumours that are dependent on these oncogenes are treated with EGFR inhibitors, KRAS pathway inhibitors (antroquinonol or AZD6244) and ALK inhibitors (crizotinib), as well as newer second‐generation inhibitors 25, 26. This evidence concerns the gene ALK and lung carcinoma.